67086-82-2

Basic information

• Product Name: 2-(4-methylphenyl)-1,3-thiazolane
• Synonyms: 2-(4-methylphenyl)-1,3-thiazolane;2-(4-Methylphenyl)thiazolidine;2-(p-Methylphenyl)thiazolidine;2-(p-Tolyl)thiazolidine;Brn 1211249;Thiazolidine, 2-(p-tolyl)-
• CAS NO: 67086-82-2
• Molecular Formula: C₁₀H₁₃NS
• Molecular Weight: 179.29
• Mol File: 67086-82-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 96～98℃
• Boiling Point: 318.5°Cat760mmHg
• Flash Point: 146.4°C
• Appearance: /
• Density: 1.088g/cm³
• Vapor Pressure: 0.00036mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: 2-(4-methylphenyl)-1,3-thiazolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methylphenyl)-1,3-thiazolane(67086-82-2)
• EPA Substance Registry System: 2-(4-methylphenyl)-1,3-thiazolane(67086-82-2)

Safety Data

• Hazardous Substances Data: 67086-82-2(Hazardous Substances Data)

Usage

Heterocyclic ring

Contains a five-membered ring with a sulfur atom and a nitrogen atom

Class

Thiazolane derivative

Usage

Commonly used in pharmaceutical and agricultural applications as a building block in the synthesis of various drugs and bioactive compounds

Importance

Potential pharmacological and therapeutic properties, valuable compound in medicinal chemistry research

Other applications

Used as a fragrance ingredient in various consumer products

InChI:InChI=1/C10H13NS/c1-8-2-4-9(5-3-8)10-11-6-7-12-10/h2-5,10-11H,6-7H2,1H3

Upstream product

• 94776-94-0 N-(4-methylphenylmethyl)cysteamine 
• 104-87-0 4-methyl-benzaldehyde 
• 60-23-1 Cysteamine 
• 156-57-0 2-mercaptoethylamine hydrochloride 

Downstream Products

• 112562-00-2 2-p-Tolyl-thiazolidine-3-carbothioic acid methylamide 
• 67189-32-6 3-methyl-2-p-tolyl-thiazolidine 

Relevant articles and documents

Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias

Blockade of the Kv1.5 ion channel is a potentially atrial-selective avenue for the treatment of atrial fibrillation and atrial flutter. The development and biological evaluation of a series of thiazolidine-based blockers of Kv1.5 is described.

Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof

New thiazolidine compounds of the formula (I) having anti-ulcer activity are disclosed: STR1 wherein Ar is a 2-furyl or a phenyl, naphthyl or pyridyl group optionally substituted by one or more C1-4 -alkyl, C1-4 -alkoxy, halo-C1

2-Phenyl thiazolidine derivatives as radioprotective agents

31 derivatives of 2-phenyl thiazolidine were submitted to radio-pharmacological tests on mice. They usually present little toxicity and some of them show a rather interesting activity.